All In Biotech

Drug Trial Radar · NCT03475953

A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

Last checked: Nov 19, 2026Latest source record: Mar 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

747

Planned (sponsor's estimate)

Start

May 4, 2018

Primary completion

Dec 31, 2024

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Institut BergoniéAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Bayer; Merck KGaA, Darmstadt, Germany
First posted
Mar 23, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been determined (phase I trial). Assessement of the efficacy and safety of a low-dose of regorafenib (80mg/day) with avelumab in patients with advanced or metastatic colorectal tumors.

Conditions

  • Colorectal Cancer Not MSI-H or MMR-deficient
  • GIST
  • Oesophageal or Gastric Carcinoma
  • Biliary Tract Cancer
  • Hepatocellular Carcinoma
  • Soft-tissue Sarcoma
  • Thyroid Cancer
  • Gastro-enteropancreatic Neuroendocrine Tumor
  • Non-small Cell Lung Cancer
  • Solid Tumor, Adult
  • Urothelial Carcinoma
  • HPV-Related Carcinoma
  • Triple Negative Breast Cancer
  • Renal Carcinoma
  • Mesotheliomas Pleural

Interventions

  • Phase 1 : RegorafenibDrug

    A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.). Patients will be allocated 3 dose levels of Regorafenib following a 3 + 3 design.

  • Phase 1 : AvelumabDrug

    A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.). Avelumab will be administered on cycle 1 Day 15 as a 1-hour intravenous (IV) infusion (10mg/kg), repeated every two weeks thereafter (ie. Day 1 and Day 15 of each subsequent cycle, as a 1-hour intravenous infusion).

  • Phase 2 : RegorafenibDrug

    Phase 2 : Regorafenib - All patients will be treated at the RP2D of regorafenib defined in the preliminary phase 1 trial with the same schedule as in the phase I.

  • Phase 2 : AvelumabDrug

    Phase 2 : Avelumab - All patients will be treated with avelumab with the same schedule as in the phase 1 trial.

  • Phase 2: low-dose RegorafenibDrug

    Phase 2 : Regorafenib - All patients will be treated at a fixed low-dose of regorafenib of 80 mg/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PHASE I : Recommended phase II dose (RP2D)Time frame: During the first cycle (28 days)
  2. PHASE II (7cohorts A, C, D, E, F and G) : Assessment of the antitumor activity of regorafenibTime frame: Throughout the treatment period, an average of 6 months
  3. Phase II (cohorts B, H, I, M, N, O and P): Assessment of the antitumor activity of regorafenibTime frame: 6 months
  4. Phase II (cohort A'): Assessment of the antitumor activity of regorafenibTime frame: 4 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Institut Bergonié

    Bordeaux, France · Recruiting

  • Centre Hospitalier Régional Universitaire - CHU Morvan

    Brest, France · Recruiting

  • Centre Léon Bérard

    Lyon, France · Recruiting

  • Institut de Cancérologie de Montpellier

    Montpellier, France · Recruiting

  • Institut Curie

    Paris, France · Recruiting

  • IUCT Oncopôle - Institut Claudius Regaud

    Toulouse, France · Recruiting

  • Institut Gustave Roussy

    Villejuif, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.